A Real-World Study on the Day and Night-Time Symptoms Among Greek COPD Patients Who Recently Initiated Treatment with Dual Bronchodilation: The DANICO Study

References

• GOLD. Global initiative for chronic obstructive lung disease; 2019. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed March 21, 2022.
   Google Scholar
• Agusti A, Hedner J, Marin JM, Barbé F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20(121):183–194. doi:10.1183/09059180.00004311
   PubMedGoogle Scholar
• Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstruct Pulmon Dis. 2013;8:595–603. doi:10.2147/COPD.S48570
   PubMed Web of Science ®Google Scholar
• Scichilone N, Incalzi RA, Blasi F, et al. Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study. BMC Pulm Med. 2019;19(1):171. doi:10.1186/s12890-019-0935-2
   PubMed Web of Science ®Google Scholar
• Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. doi:10.1186/1471-2466-14-178
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15(1):123. doi:10.1186/s12931-014-0123-0
   PubMed Web of Science ®Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16(1):92. doi:10.1186/s12931-015-0250-2
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Chapman K, Chuecos F, Ribera A, Gil EG. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J Chron Obstr Pulm Dis. 2016;11:2041–2053. doi:10.2147/COPD.S114566
   PubMed Web of Science ®Google Scholar
• Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;12(12):CD011594. doi:10.1002/14651858.CD011594.pub2
   PubMed Web of Science ®Google Scholar
• Plate T, Friedrich FW, Beier J. Effectiveness and tolerability of LABA/LAMA fixed-dose combinations aclidinium/formoterol, glycopyrronium/indacaterol and umeclidinium/vilanterol in the treatment of COPD in daily practice - results of the non-interventional DETECT study. Int J Chron Obstruct Pulmon Dis. 2020;15:1335–1347. doi:10.2147/COPD.S252354
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Oishi K, Miravitlles M, Anzueto A. Time to revise COPD treatment algorithm. Int J Chron Obstruct Pulmon Dis. 2019;14:2229–2234. doi:10.2147/COPD.S219051
   PubMed Web of Science ®Google Scholar
• Summary of the European Public Assessment Report (EPAR) for Brimica Genuair. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair. Accessed March 21, 2022.
   Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Mocarski M, Zaiser E, Trundell D, Make BJ, Hareendran A. Evaluation of the psychometric properties of the nighttime symptoms of COPD instrument. Int J Chron Obstruct Pulmon Dis. 2015;10:475–487. doi:10.2147/COPD.S75776
   PubMed Web of Science ®Google Scholar
• Garrow AP, Khan N, Tyson S, Vestbo J, Singh D, Yorke J. The development and first validation of the Manchester Early Morning Symptoms Index (MEMSI) for patients with COPD. Thorax. 2015;70(8):757–763. doi:10.1136/thoraxjnl-2014-206410
   PubMed Web of Science ®Google Scholar
• Hareendran A, Palsgrove AC, Mocarski M, et al. The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2013;11:104. doi:10.1186/1477-7525-11-104
   PubMed Web of Science ®Google Scholar
• Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The disease burden of chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2016;11(1):2179–2189. doi:10.2147/COPD.S110373
   PubMed Web of Science ®Google Scholar
• Mitsiki E, Bania E, Varounis C, Gourgoulianis KI, Alexopoulos EC. Characteristics of prevalent and new COPD cases in Greece: the GOLDEN study. Int J Chron Obstruct Pulmon Dis. 2015;10:1371–1382. doi:10.2147/COPD.S81468
   PubMed Web of Science ®Google Scholar
• Kostikas K, Vassilakopoulos TI, Tzanakis N, et al. A real-world observational study examining the impact of aclidinium bromide therapy on the quality of life, symptoms, and activity impairment of patients with chronic obstructive pulmonary disease: the Greek ON-AIR study. Int J Chron Obstruct Pulmon Dis. 2020;15:515–526. doi:10.2147/COPD.S239044
   PubMed Web of Science ®Google Scholar
• Tzanakis N, Koulouris N, Dimakou K, et al. Classification of COPD patients and compliance to recommended treatment in Greece according to GOLD 2017 report: the RELICO study. BMC Pulm Med. 2021;21(1):216. doi:10.1186/s12890-021-01576-6
   PubMed Web of Science ®Google Scholar
• Koulouris N, Dimakou K, Gourgoulianis K, et al. Self-perceived quality of sleep among COPD patients in Greece: the SLEPICO study. Sci Rep. 2022;12:540. doi:10.1038/s41598-021-04610-z
   PubMed Web of Science ®Google Scholar
• Watz H, Troosters T, Beeh KM, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558. doi:10.2147/COPD.S143488
   PubMed Web of Science ®Google Scholar
• Claus Vogelmeier C, Paggiaro PL, Dorca J, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a Phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039. doi:10.1183/13993003.00216-2016
   PubMed Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Chuecos F, Muñoz A, Gil EG. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with Aclidinium/formoterol. Respir Res. 2017;18(1):106. doi:10.1186/s12931-017-0583-0
   PubMed Web of Science ®Google Scholar
• D’Urzo AD, Singh D, Donohue JF, Chapman KR. Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. Ther Adv Respir Dis. 2019;13:1753466619850725. doi:10.1177/1753466619850725
   Web of Science ®Google Scholar
• Worth H, Buhl R, Criée CP, Kardos P, Lossi NS, Vogelmeier CF. GOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational study. Respir Med. 2017;131:77–84. doi:10.1016/j.rmed.2017.08.008
   PubMed Web of Science ®Google Scholar
• Saturni S, Bellini F, Braido F, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27(2):129–138. doi:10.1016/j.pupt.2014.01.005
   PubMed Web of Science ®Google Scholar